BioNTech's Q4 Results Wowed but Were Just the Tip of the Iceberg
It's been a whirlwind for BioNTech (NASDAQ: BNTX) over the last 12 months or so. The German biotech developed what would eventually become the first COVID-19 vaccine to win Emergency Use Authorization (EUA) in the U.S. Its partnership with Pfizer (NYSE: PFE) enabled that vaccine to be produced and distributed in mass quantities.
BioNTech gave the first look at the financial fruits of its efforts when it announced fourth-quarter results before the market opened on Tuesday. The biotech stock jumped more than 3% in early trading. Here are the highlights from BioNTech's fourth-quarter update.
Image source: Getty Images.
Source Fool.com
